Top Qs
Timeline
Chat
Perspective

Cenegermin

Pharmaceutical drug From Wikipedia, the free encyclopedia

Remove ads

Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor.[4] Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).[4]

Quick Facts Clinical data, Trade names ...

The most common side effects include eye pain and inflammation, increased lacrimation (watery eyes), pain in the eyelid and sensation of a foreign body in the eye.[5]

It was approved for medical use in the European Union in July 2017,[5] and in the United States in 2018.[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6]

Remove ads

Medical uses

Cenegermin is indicated for the treatment of neurotrophic keratitis.[4][5]

Society and culture

Names

Cenegermin is the international nonproprietary name.[7] It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli.[7]

Cenegermin is sold under the brand name Oxervate.[4][5]

References

Further reading

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads